Correlation of P53 expression and TP53 mutation in stage I lung adenocarcinoma and the predictive value for postoperative recurrence within 5 years.
P53 mutant expression predicts TP53 mutations with high sensitivity and specificity.
Correlation of P53 expression and TP53 mutation in stage I lung adenocarcinoma and the predictive value for postoperative recurrence within 5 years.
This study seeks to explore the correlation between P53 expression and TP53 mutations in stage I lung adenocarcinoma, while also assessing their predictive value for postoperative recurrence within 5 years.
Next-generation sequencing (next-generation sequencing) of the TP53 gene and immunohistochemistry (immunohistochemistry) for P53 protein were performed on formalin-fixed paraffin-embedded (formalin-fixed paraffin-embedded) tissue samples from 191 patients diagnosed with stage I lung adenocarcinoma.
P53 mutant expression correctly flags most true TP53 mutations, rarely mislabels wild-type as mutant
Two thresholds for P53 overexpression were established: 40% for predicting TP53 mutations, determined through ROC curve analysis, and 60% for predicting recurrence, utilizing X-tile software.
We defined P53 mutant expression as either overexpression (>40%) or null-expression (0%) and P53 aberrant expression as overexpression (>60%).
No significant differences in survival outcomes were observed among the distinct P53 mutant expression patterns and TP53 mutation types.
In survival analysis, TNM stage, histopathology grade, P53 aberrant expression and TP53 missense mutation were recognized as independent prognostic factors in stage I lung adenocarcinoma.
Based on our study's criteria, P53 mutant expression may serve as a surrogate marker for TP53 mutations, while P53 aberrant expression, along with TP53 missense mutation could potentially predict postoperative recurrence within five years for patients with stage I lung adenocarcinoma.
The biomarkers of TP53 mutation, P53 mutant expression and P53 aberrant expression present opportunities for enhanced risk stratification and the formulation of personalized treatment strategies.